Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Research, science & health

The dual effect of leriglitazone in X-linked Adrenoleukodystrophy (X-ALD)

Published on: 28/06/2024 Reading time: 1 min
Lésions d’un patient à l’inclusion dans le protocole (M0) disparues après 2 ans de traitement à la Leriglitazone (M24)

In 2023, the team led by Professor Fanny Mochel (AP-HP, Sorbonne University), a Paris brain Institute researcher, showed that daily dose of leriglitazone slow down the progression of myelopathy in patients with X-linked adrenoleukodystrophy, and above all, reduce their risk to develop an acute cerebral form (CALD) of the disease. This year, in scientific paper published in Brain, the same team has shown that leriglitazone can halt the progression of CALD.

The cerebral form of X-linked adrenoleukodystrophy (CALD) is an aggressive inflammation of the brain resulting in cerebral demyelination and rapid cognitive and motor decline, with a median survival of 3 years. CALD develops in a third of boys and over half of men with X-linked adrenoleukodystrophy, the most common hereditary white matter disease.

While transplantation of hematopoietic stem cells – the cells that generate the brain’s immune cells – is the gold standard in the early stages of the disease, many male patients are ineligible because of their age, the lack of a suitable donor or the presence of lesions in the corticospinal tract.

Lésions d’un patient à l’inclusion dans le protocole (M0) disparues après 2 ans de traitement à la Leriglitazone (M24)
One patient's lesions at protocol inclusion (M0) disappeared after 2 years of Leriglitazone treatment (M24)

A molecule with multiple effects

Leriglitazone, developed by the Spanish biotech Minoryx Therapeutics, present the advantage to cross the blood-brain barrier, the protective membrane of the brain which often constitute an obstacle for neurological and psychiatric diseases treatment.

This molecule also has the ability to protect oligodendrocytes, the cells that produce myelin, to reduce the level of pro-inflammatory cytokines and thus inflammation, and to preserve neurons.

A non-invasive alternative therapeutic solution

In a therapeutic trial coordinated by Prof. Fanny MOCHEL, 13 CALD patients aged between 19 and 67 were treated orally with leriglitazone.

Each participant underwent motor and cognitive neurological examinations, magnetic resonance imaging (MRI) and blood tests every 3 months over a 24-month period.

The clinical, radiological and biological stability observed in the majority of patients over 2 years of follow-up suggests that daily dose of leriglitazone can halt cerebral inflammation and disease progression. We are now awaiting a marketing authorization application from the competent authority (European Medicines Agency) to propose this treatment to patients not eligible for transplantation.

Fany Mochel Researcher at Paris Brain Institute

Sources

Golse M, Weinhofer I, Blanco B, et al. Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy. Brain. 2024 Jun 4.
https://doi.org/10.1093/brain/awae169

Our news on the subject

Interneurones. Crédit : UCLA Broad Stem Cell Research Center.
Stimulating specific neurons in the striatum stops compulsive behaviour
What if we could resist compulsions? These irrational behaviours, particularly common in obsessive-compulsive disorder (OCD), are hard to suppress. At Paris Brain Institute, Éric Burguière's team shows that we can anticipate them and block them ...
09.10.2024 Research, science & health
Les nerfs moteurs présents dans la moelle épinière se projettent vers la périphérie, où ils entrent en contact avec les muscles, formant des connexions appelées jonctions neuromusculaires. Crédit : James N. Sleigh.
Ultrasound show unexpected effects on motor neuron disease
Over the past fifteen years, neurosurgeons have been perfecting a fascinating technique: using ultrasound to temporarily open the blood-brain barrier to facilitate the action of therapeutic molecules in the central nervous system. At Paris Brain ...
09.05.2024 Research, science & health
Un neurone
Rett syndrome: a new gene therapy on the way
Gene therapy could be our best chance of treating Rett syndrome, a neurological disorder that causes severe intellectual and motor impairments. At Paris Brain Institute, Françoise Piguet and her colleagues have looked closely at brain cholesterol ...
07.16.2024 Research, science & health
Une tête de statue de l'île de Pâques sur laquelle sont posées des éléctrodes
A multimodal approach to better predict recovery in patients with disorders of consciousness
When a patient is admitted to intensive care due to a disorder of consciousness—such as a coma—establishing their neurological prognosis is a crucial yet challenging task. To reduce the uncertainty that precedes the medical decision, a group of ...
05.30.2024 Research, science & health
Population de bactéries commensales (en rouge) dans un intestin grêle de souris. Crédit : University of Chicago
The composition of the gut microbiota could influence decision-making
The way we make decisions in a social context can be explained by psychological, social, and political factors. But what if other forces were at work? Hilke Plassmann and her colleagues from the Paris Brain Institute and the University of Bonn show ...
05.16.2024 Research, science & health
Leucodystrophie
New gene therapy for metachromatic leukodystrophy proves effective in mice
Metachromatic leukodystrophy is a rare genetic disorder that mainly affects young children and results in severe neurological symptoms accompanied by a loss of motor and intellectual capacities. At Paris Brain Institute, Françoise Piguet and her ...
04.22.2024 Research, science & health
See all our news